Dr. Artem Cherkasov is co-PI on two CFI Exceptional Opportunity Fund grants awarded November 2020.
Ninadh D’Costa, PhD student in Dr. Alan So's lab, was awarded the Kidney Cancer Research Network of Canada (KCRNC)-SOPER Foundation Grant for her project titled “Identification and validation of a comprehensive gene signature to determine treatment response and guide precision oncology on patients with metastatic clear-cell renal cell carcinoma”.
Dr. Daksh Thaper has been awarded the prestigious Congressionally Directed Medical Research Programs Early Investigator Research Award. He has received funding for his project, "Characterizing and targeting the interplay between transcription factor BRN2 and SWI/SNF chromatin remodeling complex in small cell neuroendocrine prostate cancer." Dr. Thaper is a postdoctoral fellow (PDF) in Dr. Amina Zoubeidi's lab.
Two CIHR Project Grants have been awarded to researchers at our Centre.
Dr YZ Wang and his co-applicants Drs Ci, He and Lin were the recipients of a four-year CIHR Project Grant (Spring 2020 competition) for their proposal, "The role of PRDM16 in neuroendocrine prostate cancer development and aggressiveness."
Three researchers at our Centre have received Michael Smith Foundation for Health Research 2020 awards.
Dr. Faraz Hach received a Scholar Award for his project "Computational Methods For Monitoring The Evolution Of Tumours."
An international consortium of researchers led by our Centre's Dr. Artem Cherkasov and by Dr. François Jean, Associate Professor in UBC’s Faculty of Science, Department of Microbiology and Immunology is receiving $2.1 million from CIHR for their project "Computer-aided discovery of synergistic drug combinations with Remdevisir for COVID-19 through mechanism-based drug repurposing and combinatorial organoid screening", which will use artificial intelligence to search for SARS-CoV-2 inhibitors among known drugs.
Dr. Alex Wyatt has been award a Canadian Cancer Society Impact Grant for his project, "Practical genomic stratification to enable tailored treatment of DNA repair defective prostate cancer." This five-year project will screen blood samples from metastatic castration-resistant prostate cancer patients across Canada in order to identify the subset whose tumours are defective in specific classes of DNA damage repair. These patients will be selectively treated on the basis of their results, using chemotherapy or immunotherapy.
Dr. Cherkasov and his team just published a paper in ACS Central Science describing the development of a Deep Docking technology. This AI-based approach enables virtual screening (docking) of billions of molecular structures in a rapid, yet accurate fashion. Deep Docking provides up to 100-fold data reduction and 6000-fold data enrichment for candidate drug molecules. Among other applications, the developed AI-approach allowed rapid screening of 1.36 billion molecules against a critical drug target in COVID-19.
Elie Ritch and Evan Warner of Dr. Wyatt's lab have been awarded CIHR Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Awards.
The funded projects are “Genomic and clinical characteristics of the hyper-mutant molecular subtype of advanced metastatic prostate cancer studied using circulating tumor DNA” (Ritch) and “Genomic features of metastatic prostate cancer with aberrant DNA damage repair” (Warner).